Skip to main content
Premium Trial:

Request an Annual Quote

PE Files for Follow-on Celera Stock Offering

Premium

R

OCKVILLE, Md.--PE announced that it has filed with the Securities and Exchange Commission for a follow-on public offering of 1.615 million shares of its Celera Genomics common stock. The number of shares to be sold does not reflect the previously announced two-for-one Celera stock split effective February 18. The net proceeds from the offering are intended primarily to fund Celera’s new product and technology development activities in functional genomics, with an emphasis on proteomics, and personalized health/medicine. Celera also intends to use the capital for general corporate purposes, including possible acquisitions, alliances, or collaborations.

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.